Renovaro Biosciences Inc. (RENB)
NASDAQ: RENB · IEX Real-Time Price · USD
2.705
-0.085 (-3.05%)
Mar 28, 2024, 9:59 AM EDT - Market open

Renovaro Biosciences Income Statement

Millions USD. Fiscal year is Jul - Jun.
Year 2023202220212020201920182017
Selling, General & Admin
15.3214.337.567.128.423.90.93
Research & Development
4.178.3715.724.692.50.620.06
Other Operating Expenses
19.0793.380.120.110.070.811.4
Operating Expenses
38.56116.0823.411.9210.995.332.4
Operating Income
-38.56-116.08-23.4-11.92-10.99-5.33-2.4
Interest Expense / Income
0.580.370.380.100.140.03
Other Expense / Income
0.55-3.023.07-0.617.030.95-0.22
Pretax Income
-39.68-113.43-26.85-11.42-18.02-6.42-2.21
Income Tax
00-0.1300-0.11-0.06
Net Income
-39.68-113.43-26.72-11.42-18.02-6.31-2.14
Shares Outstanding (Basic)
56534746382212
Shares Outstanding (Diluted)
56534746382212
Shares Change
7.11%11.37%1.81%23.38%71.15%78.87%-
EPS (Basic)
-0.71-2.16-0.57-0.25-0.48-0.29-0.17
EPS (Diluted)
-0.71-2.16-0.57-0.25-0.48-0.29-0.17
Free Cash Flow
-11.8-15.74-20.66-10.64-9.22-4.37-1.18
Free Cash Flow Per Share
-0.21-0.30-0.44-0.23-0.25-0.20-0.10
EBITDA
-38.99-112.94-26.35-10.95-17.94-6.26-2.17
Depreciation & Amortization
0.110.120.120.370.070.020.01
EBIT
-39.1-113.06-26.47-11.31-18.02-6.28-2.18
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).